Log in

Relevant bibliographies by topics / Bronchodilators agents

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Bronchodilators agents'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Bronchodilators agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Bronchodilators agents"

1

Abukwaik, Aya Wail, Rupal Mansukhani, and Mary Barna Bridgeman. "Long-Acting Bronchodilator Use in the Management of Stable COPD." Annals of Pharmacotherapy 52, no. 6 (2017): 562–70. http://dx.doi.org/10.1177/1060028017746697.

Full text

Abstract:

Objective: To review the management of chronic obstructive pulmonary disease (COPD), with a focus on updated information regarding the use of long-acting bronchodilators in the prevention of exacerbations and outcomes associated with this disease. Data Sources: A literature search of the MEDLINE databases through November 2017 was conducted. All published articles regarding use of bronchodilator therapy in the management of COPD were evaluated. References of selected articles, data from poster presentations, and abstract publications were additionally reviewed. Study Selection and Data Extract

APA, Harvard, Vancouver, ISO, and other styles

2

Choi, Hayoung, Hyun Lee, Seung Won Ra, and Yeon-Mok Oh. "Update on pharmacotherapy for adult bronchiectasis." Journal of the Korean Medical Association 63, no. 8 (2020): 486–92. http://dx.doi.org/10.5124/jkma.2020.63.8.486.

Full text

Abstract:

Bronchiectasis refers to abnormal dilatation of the bronchi, which leads to the failure of mucus clearance and increased risk of infection. Pharmacotherapy for stable bronchiectasis includes oral or inhaled mucoactive agents, anti-inflammatory therapy, inhaled bronchodilators, long-term antibiotics, and long-term macrolide treatment. Among them, mucoactive agents are the most common adjunctive agents to airway clearance techniques. When patients with impaired lung function suffer from dyspnea, inhaled bronchodilators may be prescribed to relieve the symptom. Long-term macrolide treatment has b

APA, Harvard, Vancouver, ISO, and other styles

3

Somand, Heather, and Tami L. Remington. "Tiotropium: A Bronchodilator for Chronic Obstructive Pulmonary Disease." Annals of Pharmacotherapy 39, no. 9 (2005): 1467–75. http://dx.doi.org/10.1345/aph.1e469.

Full text

Abstract:

OBJECTIVE: To review the scientific literature evaluating the efficacy and tolerability of tiotropium bromide, a new bronchodilator indicated for treatment of chronic obstructive pulmonary disease (COPD). DATA SOURCES: Articles were identified through searches of MEDLINE (1966–January 2005) using the key words tiotropium, BA 679 BR, chronic obstructive pulmonary disease, and anticholinergic agents. Additional citations were identified from bibliographies of publications cited. STUDY SELECTION AND DATA EXTRACTION: Experimental and observational studies of tiotropium bromide were selected. Trial

APA, Harvard, Vancouver, ISO, and other styles

4

Beauchesne, Marie-France. "Management of Chronic Obstructive Pulmonary Disease: A Review." Journal of Pharmacy Practice 14, no. 2 (2001): 126–42. http://dx.doi.org/10.1106/777c-kd4j-ym5x-xw1m.

Full text

Abstract:

Chronic obstructive pulmonary disease (COPD) affects about 14 million persons in the United States and is the only common cause of death that is increasing in incidence. Chronic management of this disorder includes nonpharmacologic interventions such as smoking cessation, immunization, nutritional support, and pulmonary rehabilitation. The pharmacotherapy of COPD is based on regular administration of bronchodilators, when symptoms are persistent. Long-acting bronchodilators have been shown to improve quality of life in patients with COPD. Ipratropium remains the anticholinergic of choice, but

APA, Harvard, Vancouver, ISO, and other styles

5

Yakubova, Z. N. "Corrigibility of respiratory mechanics in patients with pre-asthma and bronchial asthma." Kazan medical journal 67, no. 1 (1986): 19–21. http://dx.doi.org/10.17816/kazmj62899.

Full text

Abstract:

Respiratory mechanics on a pneumotachograph was studied in 30 patients with preasthma, proceeding against a background of chronic bronchitis, and in 35 patients with bronchial asthma of medium severity (according to classification of A.D. Ado and P.K. Bulatov, 1969). Complex therapy included anti-inflammatory, desensitizing drugs and agents improving bronchial drainage function - bronchodilators.

APA, Harvard, Vancouver, ISO, and other styles

6

Gustafsson, B., and C. G. Persson. "Effect of different bronchodilators on airway smooth muscle responsiveness to contractile agents." Thorax 46, no. 5 (1991): 360–65. http://dx.doi.org/10.1136/thx.46.5.360.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Cheng, Shih-Lung. "Comparison of Effectiveness Using Different Dual Bronchodilator Agents in Chronic Obstructive Pulmonary Disease Treatment." Journal of Clinical Medicine 10, no. 12 (2021): 2649. http://dx.doi.org/10.3390/jcm10122649.

Full text

Abstract:

The effectiveness and safety of fixed dual long-acting bronchodilators for chronic obstructive pulmonary disease (COPD) patients have been well established; however, there is a paucity of clinical effectiveness comparison in patients with COPD treatment. The aim of the current study was to compare the effectiveness of three once-daily dual bronchodilator agents in patients with COPD. Patients with diagnosed COPD and treated with a long-acting beta-agonist (LABA) + long-acting muscarinic antagonist (LAMA) fixed-dose combination therapy (UME/VIL (umeclidinium and vilanterol inhalation powder), I

APA, Harvard, Vancouver, ISO, and other styles

8

&NA;. "Episodes of acute severe asthma require aggressive treatment with bronchodilators, corticosteroids and other agents." Drugs & Therapy Perspectives 26, no. 8 (2010): 9–13. http://dx.doi.org/10.2165/11205320-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hayallah, Alaa K. M., Ahmad A. Talhouni, and Abdel Alim M. Abdel Alim. "Design and synthesis of new 8-anilide theophylline derivatives as bronchodilators and antibacterial agents." Archives of Pharmacal Research 35, no. 8 (2012): 1355–68. http://dx.doi.org/10.1007/s12272-012-0805-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Bailey, James, and Mark Bowen. "Embracing the Cascade part 3: clinical decision making in equine asthma." UK-Vet Equine 4, no. 1 (2020): 19–29. http://dx.doi.org/10.12968/ukve.2020.4.1.19.

Full text

Abstract:

Equine asthma is the current terminology that covers chronic non-infectious lower airway disorders in the horse. Mild and moderate equine asthma reflect the syndrome previously referred to as inflammatory airway disease, while severe asthma reflects both recurrent airway obstruction and summer pasture-associated obstructive airway disease. Corticosteroids are the most important therapeutic agents for the management of horses with all severities of equine asthma. Prednisolone and dexamethasone products are authorised for use in horses and can be used for the management of asthma. Inhaled cortic

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Bronchodilators agents"

1

Wilchesky, Machelle 1965. "Arrhythmia risk associated with the use of bronchodilators in patients with chronic obstructive pulmonary disease : cohort studies and methodological issues." Thesis, McGill University, 2008. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=115713.

Full text

Abstract:

Whereas first line therapy for chronic obstructive pulmonary disease (COPD) usually includes a short-acting bronchodilator, there are suggestions that these agents may increase the risk of cardiac arrhythmias. In this thesis, we first assessed the risks associated with short-acting beta-agonists (SABA), long-acting beta-agonists (LABA), ipratropium bromide (IB), and methyl xanthines (MX) within a cohort of COPD patients using the health databases of Saskatchewan. In order to confirm these findings and to address some methodological issues we then replicated this analysis within a larger cohort

APA, Harvard, Vancouver, ISO, and other styles

2

Naves, Kattia Cristina. "Análise crítica do tratamento instituído a crianças com infecção por vírus sincicial respiratório em um hospital público." Universidade de São Paulo, 2018. http://www.teses.usp.br/teses/disponiveis/5/5141/tde-14082018-102623/.

Full text

Abstract:

Introdução: A bronquiolite aguda é a principal causa de internação de lactentes menores de um ano de idade e tem como principal agente etiológico o vírus sincicial respiratório. As principais diretrizes baseadas em evidências recomendam o tratamento de suporte com hidratação e oxigenoterapia, quando necessário e não indicam o uso rotineiro de corticosteroides, broncodilatadores e antibióticos. No entanto, estudos anteriores mostraram que o uso inadvertido dessas medicações é frequente na prática clínica. Objetivo: Analisar o tratamento aplicado a lactentes com bronquiolite viral aguda em um ho

APA, Harvard, Vancouver, ISO, and other styles

3

Melfi, James. "A descriptive study of beta2-agonist use in asthma patients based on a nationally representative sample /." View online ; access limited to URI, 2005. http://0-wwwlib.umi.com.helin.uri.edu/dissertations/dlnow/3188067.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Riley, Sean P. "Exercise-induced bronchoconstriction: mechanisms, evaluation, and treatment /." View abstract, 2000. http://library.ctstateu.edu/ccsu%5Ftheses/1610.html.

Full text

Abstract:

Thesis (M.S.)--Central Connecticut State University, 2000.<br>Thesis advisor: Ruth Rollin. " ... in partial fulfillment of the requirements for the degree of Master of Science in Biological Science[s]." Includes bibliographical references (leaves 76-80).

APA, Harvard, Vancouver, ISO, and other styles

5

Falls, Richard Drew. "SUBJECTIVE AND OBJECTIVE RESPONSES TO VARIED DOSES OF AN INHALED BRONCHODILATOR (ALBUTEROL)." Thesis, The University of Arizona, 1985. http://hdl.handle.net/10150/275382.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Scott, Mark George Hunter. "Control of cyclic AMP-mediated and ÃŸâ‚‚ adrenergic receptor gene expression in cultured human airway smooth muscle cells." Thesis, University of Nottingham, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.324123.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Vasconcelos, Thiago Brasileiro de. "Efeitos antiespasmÃdico e miorrelaxante do β-citronelol em mÃsculo liso traqueal de ratos: potencial aÃÃo na hiperreatividade apÃs desafio antigÃnico e elucidaÃÃo do mecanismo de aÃÃo." Universidade Federal do CearÃ, 2013. http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=11503.

Full text

Abstract:

Conselho Nacional de Desenvolvimento CientÃfico e TecnolÃgico<br>O β-citronelol Ã um Ãlcool monoterpÃnico de ocorrÃncia natural em vÃrios Ãleos essenciais como o Ãleo de citronela (obtido de Cymbopogon winterianus), de ampla utilizaÃÃo popular por suas propriedades repelentes de insetos. Recentemente, a esta molÃcula tem sido atribuÃdas outras propriedades que envolvem atividade antibacteriana, antifÃngica, antiespasmÃdica, hipotensora e vasorrelaxante. Sendo assim, objetivamos estudar suas possÃveis aÃÃes no comportamento motor do mÃsculo liso do sistema respiratÃrio de ratos Wistar. Os

APA, Harvard, Vancouver, ISO, and other styles

8

Hall, Jill S. "Development of an in vitro method to help predict in vivo behavior of controlled release products." View electronic thesis (PDF), 2009. http://dl.uncw.edu/etd/2009-2/hallj/jillhall.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Wang, Jianpu. "Pathophysiology and treatment of chlorine gas-induced lung injury : an experimental study in pigs /." Linköping : Univ, 2004. http://www.bibl.liu.se/liupubl/disp/disp2004/med877s.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Muchão, Fabio Pereira. "Avaliação da eficácia e segurança de doses crescentes de salbutamol, administrado através de inalador dosimetrado, em crianças e adolescentes com crise de asma." Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/5/5141/tde-06022017-151909/.

Full text

Abstract:

INTRODUÇÃO: A dosagem ideal de salbutamol através de inaladores dosimetrados para o tratamento da asma aguda na infância não está bem estabelecida. Este estudo visou comparar dois regimes de dosagem de salbutamol via inalador dosimetrado com espaçador em crianças com crises moderadas ou graves de asma. As hipóteses deste estudo foram: I. Pacientes em vigência de crises de sibilância moderadas ou graves necessitam doses de salbutamol maiores que as até recentemente recomendadas pelo Global Initiative for Asthma (GINA). II. Doses maiores de salbutamol são seguras para crianças com idade igual ou

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Bronchodilators agents"

1

Barbara, Juknialis, ed. Inhaled aerosol bronchodilators. Williams & Wilkins, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

L, Rau Joseph, ed. Rau's respiratory care pharmacology. 8th ed. Elsevier/Mosby, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Dietz, D. NTP technical report on the toxicology and carcinogenesis studies of l-Epinephrine hydrochloride (CAS No. 55-31-2) in F344/N rats and B6C3F1 mice (inhalation studies). U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

C, Soderberg Robert, ed. Principles of pharmacology for respiratory care. Delmar Publishers, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bills, Georgine W. Principles of pharmacology for respiratory care. 2nd ed. Delmar Publishers, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

L, Rau Joseph, ed. Respiratory care pharmacology. 3rd ed. Year Book Medical Publishers, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Respiratory care pharmacology. 4th ed. Mosby, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Respiratory care pharmacology. 5th ed. Mosby, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Gardenhire, Douglas S. Rau's respiratory care pharmacology. 7th ed. Mosby Elsevier, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Dhand, Rajiv, and Michael McCormack. Bronchodilators in critical illness. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0033.

Full text

Abstract:

Inhaled beta-agonists and anticholinergic agents, as well as systemically administered methylxanthines, are frequently employed to achieve bronchodilation in critically-ill patients. Inhaled agents are given by pressurized metered dose inhaler (pMDI), nebulizer, or dry powder inhaler. In ventilator-supported patients, aerosolized agents are generally only administered by pMDI or nebulizer. The ventilator circuit, artificial airway, and circuit humidity complicate the delivery of aerosolized agents, and there is a wide variability in drug delivery efficiency with various bench models of mechani

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Bronchodilators agents"

1

Gross, N. J. "BRONCHODILATORS | Anticholinergic Agents." In Encyclopedia of Respiratory Medicine. Elsevier, 2006. http://dx.doi.org/10.1016/b0-12-370879-6/00052-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Frent, Stefan-Marian. "COPD Pharmacological Management Update." In Update in Respiratory Diseases. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.90239.

Full text

Abstract:

Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and mortality worldwide. Although it is considered both preventable and treatable, COPD still represents an important public health challenge. The classes of pharmacological agents widely used for the maintenance treatment are bronchodilators (SABA, SAMA, LABA, LAMA) and inhaled corticosteroids (ICS). While it is largely accepted that inhaled bronchodilators, which are effective and well tolerated in patients with stable disease, are the cornerstone of the pharmacological management of COPD, there is an ongoing debate regarding the role of inhaled corticosteroids. This is also reflected in the last versions of the GOLD recommendations, which suffered dramatic changes in the recent years. The trend for personalized medicine led to the search for biomarkers which could guide the therapeutic decisions. Recent studies demonstrated that blood eosinophils can reasonably predict the ICS relative efficacy in preventing COPD exacerbations and thus could inform the disease management.

APA, Harvard, Vancouver, ISO, and other styles

3

Ali Kamal, Yasser. "Surgical Management of Bronchiectasis." In Update in Respiratory Diseases. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.93103.

Full text

Abstract:

Bronchiectasis is a chronic clinicopathological disease of the lung characterized by chronic cough, sputum production, recurrent pulmonary infection, and persistent bronchial dilatation on computed tomography. For many years, bronchiectasis associated with high mortality and morbidity particularly before the advent of antibiotics. The medical treatment of bronchiectasis includes antibiotic therapy, airway clearance, bronchodilators, and anti-inflammatory agents. Surgery is mainly performed for localized disease after failure of the medical treatment, including: segmentectomy, lobectomy, and pneumonectomy. This chapter highlights the current surgical considerations for treatment of bronchiectasis, regarding indications of surgery, preoperative evaluation and preparation, available operative procedures, postoperative outcomes, and other important surgical issues.

APA, Harvard, Vancouver, ISO, and other styles

4

Waldmann, Carl, Andrew Rhodes, Neil Soni, and Jonathan Handy. "Respiratory drugs." In Oxford Desk Reference: Critical Care. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198723561.003.0011.

Full text

Abstract:

This chapter discusses respiratory drugs and includes discussion on bronchodilators (describing β‎<sub>2</sub>-agonists, anticholinergic agents, and xanthine derivatives), nitric oxide (history, biochemistry, clinical use of inhaled nitric oxide, administration of inhaled nitric oxide, adverse effects of inhaled nitric oxide, and adjunctive therapies), mucolytics (properties of mucus, types of mucolytics, clinical applications, and side-effects), and helium–oxygen gas mixtures (including nomenclature, rationale, indications, expected effects, presentation, face mask administration, nebulization, patient monitoring during therapy, stopping helium–oxygen therapy, indications for helium–oxygen mask ventilation, indications for helium–oxygen intermittent positive pressure ventilation (IPPV) via endotracheal or tracheostomy tube, patient monitoring during IPPV therapy, stopping helium–oxygen therapy, and published trials).

APA, Harvard, Vancouver, ISO, and other styles

5

Graham, James D. P. "The Bronchodilator Action of Cannabinoids." In Cannabinoids as Therapeutic Agents. Chapman and Hall/CRC, 2019. http://dx.doi.org/10.1201/9780429260667-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Peters, Stephen P. "Chronic Obstructive Pulmonary Disease and Irreversible Airflow Obstruction." In Asthma. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199918065.003.0007.

Full text

Abstract:

Patients with fixed airflow obstruction, whether from asthma or chronic obstructive pulmonary disease (COPD), or an overlap phenotype, represent an especially difficult group of patients to both categorize and manage. Many of the current research activities in both asthma and COPD are designed to subclassify patients with asthma and COPD into different endotypes and phenotypes, with the hope that the results will have implications for both the natural history of disease and the response to different therapies. Data outlined in this review, particularly the genetic findings, help strengthen the “Dutch hypothesis” Orie put forth more than 50 years ago about the commonalities of obstructive airways diseases operating under a variety of environmental influences. The identification of targets distinct from inflammation in both asthma and COPD, through different mechanisms—atopy, important in asthma, and smoking, important COPD–could lead to novel treatments for both of these diseases with fixed airflow obstruction. In the meantime, the use of bronchodilators, antiinflammatory agents, and environmental control and intervention, including smoking cessation, weight loss and control, and exercise and pulmonary rehabilitation, remain the foundation of the therapeutic approach for these diseases, regardless of their origin.

APA, Harvard, Vancouver, ISO, and other styles

7

Naji, Nizar, and Paul M. O’Byrne. "Bronchiectasis." In Asthma. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199918065.003.0008.

Full text

Abstract:

Bronchiectasis is one of the most debilitating chronic respiratory diseases, which affects all ages, with significant morbidity and mortality. It is recognized clinically by chronic persistent daily cough, productive of mucopurulent sputum. The defining characteristic is the permanent abnormal dilatation and destruction of bronchial walls, which involve both the major bronchi and bronchioles. It is a major contributor to progressive lung function decline and functional disability, especially in patients with respiratory comorbidities. Bronchial hygiene, to clear airway secretions, is the basis of management. Bronchodilators and fixed-dose combination therapy with an inhaled corticosteroid and a long-acting β‎-agonist provide clinical benefit, but do not reduce the risks for acute exacerbations. The airways of patients with bronchiectasis are often colonized with pathologic bacteria, and acute exacerbations require antibiotic therapy. Allergic bronchopulmonary aspergillosis often requires daily oral corticosteroids for management.

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Bronchodilators agents"

1

Mathur, M., A. M. Al-Jumaily, G. Ijpma, and R. Alany. "Effects of Bronchodilators Combined With Oscillations on the Contracted Airway Smooth Muscle." In ASME 2010 International Mechanical Engineering Congress and Exposition. ASMEDC, 2010. http://dx.doi.org/10.1115/imece2010-38357.

Full text

Abstract:

Current asthma treatments using anti-inflammatory agents and airway smooth muscle (ASM) relaxants are expensive, variable in effectiveness and are associated with several cardiovascular side effects. Previous in vitro experiments conducted on ASM tissues suggest that oscillations applied to contracted muscle result in a reduction in the contractile ability of the tissue. This study focuses on investigating the combined effects of muscle relaxants (bronchodilators) and length oscillations on the dynamics of contracted ASM. Isolated porcine tracheal smooth muscle tissues are contracted using Ace

APA, Harvard, Vancouver, ISO, and other styles

2

Machida, Kentaro, Yukari Sadamura, Keiko Mizuno, Ikkou Higashimoto, and Hiromasa Inoue. "Bronchodilator Efficacy Of Single Administration Of Oral Anticholinergic Agent In Patients With Chronic Obstructive Pulmonary Disease." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a2919.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Bini, Francesco, Noemi Grassi, Angelo De Lauretis, Bruno Bodini, Cristina Arosio, and Adriano Vaghi. "Retrospective study on the use of LABA/LAMA therapy (long acting bronchodilator agent/long acting muscarinic agent) in patients with severe COPD at first diagnosis." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa2500.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Venkatasamy, Radhakrishnan, Clive Page, and Domenico Spina. "The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa3960.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!